World News – UA – New Medicines for Australians with Multiple Sclerosis, Lymphoma, Carcinoma and Reproductive Cancer


Beginning November 1, the Morrison government will invest over $ 86 million over the next four years to provide better access to life-saving medicines for Australians living with multiple sclerosis (MS) and various forms of cancer

MS is the most commonly acquired neurological disease in young adults with over 25,600 Australians living with multiple sclerosis and over 2 years of age 3 million affected worldwide

The average age of diagnosis is only 30, and around 75% of people with multiple sclerosis in Australia are women

There is a high clinical need for effective treatments for patients with progressive forms of relapsing multiple sclerosis

Mayzent® (siponimod) will be listed on PBS for the first time to treat these patients with secondary progressive multiple sclerosis

Without the PBS grant, these patients would pay over $ 25,000 per year for treatment, with around 800 patients benefiting from this list each year

The PBS grant now means patients will only have to pay $ 41 per prescription, or $ 660 with a concession card

In addition to this list, Australians diagnosed with a rare type of lymphoma affecting the skin will benefit from subsidized access to a new drug and specialized treatment from November 1, 2020 thanks to an investment of over 11 $ 5 million

Cutaneous T cell lymphoma is a type of non-Hodgkin lymphoma that affects the skin and causes a buildup of malignant T cells in the skin, resulting in raised patches of the skin, looking like rashes or itchy, bumps skin or ulcers and swollen lymph nodes

Uvadex® (methoxsalen) to be listed for the first time on PBS for the treatment of patients with cutaneous erythrodermic T-cell lymphoma who have not responded to other treatments

About 75 patients per year can benefit from this list Without a PBS grant, these Australians would pay more than $ 3,400 per year

At the same time, two new items will be introduced in the Medicare Benefit Schedule (MBS) for the use of extracorporeal photopheresis (ECP) in combination with Uvadex® to treat disease, as recommended by the medical services advisory committee

PKU is a type of treatment that involves attaching a patient to a machine that removes some of their blood The machine separates white blood cells and red blood cells and plasma returns to the body White blood cells are mixed with Uvadex ®, exposed to ultraviolet (UV) light, then put back into the patient PKU activates the patient’s immune system to fight cancer

Other PBS listings from November 1 – announced in the 2020-2021 budget – include the expanded list of:

Since 2013, the Australian government has approved more than 2,450 new or amended listings on the PBS

This works out to an average of around 30 announcements or changes per month – or one per day – for an overall government investment of USD 118 billion

The Morrison government’s commitment to ensuring Australians can access affordable medicine, when they need it, remains strong

Medicine, Drug Benefit Plan, Multiple Sclerosis, Greg Hunt, siponimod

News from the world – UA – New drugs for Australians with multiple sclerosis, lymphoma, carcinoma and reproductive cancers



Donnez votre point de vue et aboonez-vous!



Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]